IP Library › Granted Patent US 7,101,680
Granted Patent B2
US 7,101,680 · App. 09/971,740 · Granted Sep 5, 2006

Method for detecting the presence of monomeric brain associated human glutamine synthetase

Assignee: Syn X Pharma, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,101,680
App. No.
09/971,740
Granted
Sep 5, 2006
Kind
B2
Abstract

A method for diagnosing Alzheimer's disease(AD) is disclosed. The method involves directly detecting the presence of a biochemical marker, specifically human glutamine synthetase, in bodily fluid, preferably blood or a blood product. The detection is by an immunoassay incorporating an antibody specific to human glutamine synthetase. In addition, a method for distinguishing between AD and non-AD dementia is disclosed.

Claims (3)

1. A method for detecting monomeric brain associated human glutamine synthetase in a sample using a monoclonal antibody produced against human glutamine synthetase, whereby said monoclonal antibody is specific for monomeric brain associated human glutamine synthetase having a molecular weight of about 44 kDa, which comprises contacting the sample with the monoclonal antibody and detecting specific binding of the monoclonal antibody to monomeric brain associated human glutamine synthetase whereby said monomeric brain associated human glutamine synthetase in said sample is detected.

2. A method for detecting monomeric brain associated human glutamine synthetase in a sample using a monoclonal antibody encoded by the clone deposited with the ATCC as Accession Number PTA-3339, whereby said monoclonal antibody is specific for monomeric brain associated human glutamine synthetase having a molecular weight of about 44 kDa, which comprises contacting said sample with said monoclonal antibody and detecting specific binding of said monoclonal antibody to monomeric brain associated human glutamine synthetase whereby said monomeric brain associated human glutamine synthetase in said sample is detected.

3. A method for detecting monomeric brain associated human glutamine synthetase in a sample using a monoclonal antibody encoded by the clone deposited with the ATCC as Accession Number PTA-3340, whereby said nonoclonal antibody is specific for monomeric brain associated human glutamine synthetase having a molecular weight of about 44 kDa, which comprises contacting said sample with said monoclonal antibody and detecting specific binding of said monoclonal antibody to monomeric brain associated human glutamine synthetase whereby said monomeric brain associated human glutamine synthetase in said sample is detected.

Assignments (8)
GRANT OF SECURITY INTEREST Recorded Jul 25, 2008
From: NANOGEN, INC.
To: PORTSIDE GROWTH & OPPORTUNITY FUND, AS COLLATERAL AGENT
Reel/Frame 021291/0605 →
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2008
From: NANOGEN POINT OF CARE, INC.
To: NANOGEN, INC.
Reel/Frame 020826/0087 →
ASSIGNMENT OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Apr 15, 2008
From: THE CANADA TRUST COMPANY
To: NANOGEN, INC.
Reel/Frame 020807/0247 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2006
From: NANOGEN POINT OF CARE INC.
To: NANOGEN INC.
Reel/Frame 018227/0106 →
CHANGE OF NAME Recorded Jul 3, 2006
From: SYN X PHARMA INC.
To: NANOGEN POINT OF CARE INC.
Reel/Frame 017881/0648 →
SECURITY INTEREST Recorded Feb 12, 2004
From: SYNX PHARMA INC.
To: NANOGEN, INC.
Reel/Frame 014337/0010 →
SECURITY AGREEMENT Recorded Jul 18, 2003
From: SYNX PHARMA INC.
To: CANADA TRUST COMPANY, THE
Reel/Frame 014242/0790 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2001
From: JACKOWSKI, GEORGE; TAKAHASHI, MIYOKO
To: SYN X PHARMA
Reel/Frame 012268/0743 →
Continuity (2)
Continuation 0984207900 · Apr 25, 2001
Related Publication 20020160425A1 · Oct 31, 2002